MannKind Corporation (NASDAQ:MNKD) VP Juergen Martens sold 76,899 shares of the company’s stock on the open market in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $7.50, for a total transaction of $576,742.50. Following the sale, the vice president now directly owns 139,024 shares of the company’s stock, valued at approximately $1,042,680. MannKind Corporation (NASDAQ:MNKD) weekly performance is 10.68%. On last trading day company shares ended up $7.77. Analysts mean target price for the company is $8.07. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 23.88%.
Sigma-Aldrich Corporation (NASDAQ:SIAL) a leading Life Science and Technology company, announced it will be presenting the investor conferences in June: Jefferies Global Healthcare Conference 2014 on Monday, June 2, 2014 in New York City, presenting at 1:30 PM (Eastern). Sigma-Aldrich Corporation (NASDAQ:SIAL) shares advanced 0.64% in last trading session and ended the day on $97.69. Gross Margin is 50.30 % and its return on assets is 13.10%. Sigma-Aldrich Corporation (NASDAQ:SIAL) quarterly performance is 5.01%.
Zacks reaffirmed their neutral rating on shares of Merck & Co. Inc (NYSE:MRK) in a report released on Tuesday. Zacks currently has a $59.00 price objective on the stock. Merck & Co., Inc. (NYSE:MRK) shares moved up 0.57% in last trading session and was closed at $56.81, while trading in range of $56.45 – $56.98. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 14.40%.
Pfizer Inc. (NYSE:PFE) announced detailed results from the Oral treatment Psoriasis Trial (OPT) Retreatment study (A3921111), a Phase 3 study investigating tofacitinib for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. This three-period study showed that tofacitinib, as a 5 mg or 10 mg pill taken twice daily, met its two primary efficacy endpoints. The safety profile of tofacitinib in OPT Retreatment was consistent with previous studies and there were no new safety findings in this trial. Pfizer Inc. (NYSE:PFE) ended the last trading day at $29.49. Company weekly volatility is calculated as 1.39% and price to cash ratio as 1.39. Pfizer Inc. (NYSE:PFE) showed a positive weekly performance of 1.27%.
Chemicals giant BASF SE (ADR) (OTCMKTS:BASFY) says the shale gas boom currently underway in the U.S. offers the business “an outstanding opportunity” in that market, but its impact on its European operations would be more limited. BASF SE (ADR) (OTCMKTS:BASFY) On last trading day company shares ended up $113.35 .